Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2006

Study Completion Date

July 31, 2011

Conditions
Non-Hodgkin Lymphoma
Interventions
DRUG

Radioimmunotherapy

PROCEDURE

allogeneic hematopoietic cell transplantation

Trial Locations (11)

12200

Medical Center Charite Benjamin Franklin, Berlin

30625

Medical Center University of Hannover, Hanover

37099

Medical Center University of Goettingen, Göttingen

45122

Center for Marrow Transplantation, University of Essen, Essen

48149

Medical Center University of Muenster, Münster

65191

Stiftung Deutsche Klinik für Diagnostik GmbH, Wiesbaden

72076

South West German Cancer Center, University of Tuebingen Medical Center, Tübingen

89081

Medical Center University of Ulm, Ulm

D-01307

University of Dresden Medical Center, Dresden

04103

Medical Center University of Leipzig, Leipzig

D-97070

University of Wuerzburg Medical Center, Würzburg

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER

NCT00302757 - Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter